gilteritinib fumarate · Astellas · NDA 211349
Xospata
Earliest generic entry, as listed
1 Jul 2036
Blocked by patent: US 10786500, US 11938130, US 11938131, US 11938132, US 11938133, US 11944620.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10786500 | drug product · sets the listed date | 1 Jul 2036 |
| US 11938130 | drug product · sets the listed date | 1 Jul 2036 |
| US 11938131 | drug product · sets the listed date | 1 Jul 2036 |
| US 11938132 | drug product · sets the listed date | 1 Jul 2036 |
| US 11938133 | drug product · sets the listed date | 1 Jul 2036 |
| US 11944620 | drug product · sets the listed date | 1 Jul 2036 |
| US 8969336 | drug substance, drug product | 28 Nov 2032 |
| US 9487491 | use U-2456 | 28 Jul 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211349 · 001 · RLD | tablet, oral | EQ 40MG BASE | 1 Jul 2036 |